INTEGRILIN 0.75MG/ML 100ML VIAL ZAF (Eptifibatide)

Eptifibatide works by inhibiting the glycoprotein IIb/IIIa receptor on platelets, thereby preventing platelets from aggregating and forming blood clots. This helps to prevent the formation of new blood clots and reduces the risk of complications such as heart attack or stroke.

Integrilin is typically administered intravenously by healthcare professionals during or after procedures such as PCI, or as a continuous infusion in patients with acute coronary syndromes. The dosage and duration of treatment depend on various factors, including the patient’s medical condition and the specific procedure being performed.

As with any medication, Integrilin can cause side effects, though they are generally uncommon. Common side effects may include bleeding, headache, nausea, vomiting, or injection site reactions. Serious side effects such as severe bleeding or allergic reactions are rare but possible.

It’s essential for healthcare providers to carefully monitor patients receiving Integrilin, particularly for signs of bleeding, and to use it with caution in patients with a history of bleeding disorders or other medical conditions that increase the risk of bleeding. The dosage and administration of Integrilin should be individualized based on factors such as the patient’s weight, renal function, and other medications they may be taking.